Pathological hyperpermeability accompanies many blinding retinopathies. Despite 13 important therapeutic breakthroughs benefitting many but not all retinopathy patients, 14 the intracellular signalling underlying retinal leakage is still poorly understood. We 15 have developed an ex-vivo model, which allowed us to measure and manipulate acute 16 vascular permeability in the intact rodent retina, and combined measurements with 17 immunohistochemical analyses of signal transduction. This ex-vivo retina platform 18 proved to be an easily accessible and reliable tool for systematic identification of 19 regulators of vascular permeability through small molecule antagonists/agonists and 20 siRNA. By using this model, we showed that AMPK was a key mediator of VEGF-and 21 bradykinin-induced permeability by acting downstream of Ca 2+ and CAMKK, and 22 upstream of eNOS/VE-cadherin as well as p38/HSP27. Accordingly, AMPK agonist 23 potently induced retinal vascular leakage, a finding of major importance for their use 24 as therapeutic agents in the treatment of e.g. cancer or metabolic syndrome. 25 26 489 490 1 Nagy, 500 5 Ford, J. A. et al. Current treatments in diabetic macular oedema: systematic review and meta-501 analysis. BMJ Open 3, 504 7 Canning, P. et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target 505 to prevent retinal vasopermeability during diabetes. of phospholipase C, protein 510 kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 276, H535-511 542,
INTRODUCTION 27
Leakage within the vascular system is the consequence of endothelial 28 hyperpermeability, which leads to extravasation of fluids and proteins, resulting in 29 interstitial oedema. Vascular leakage can be the cause or a significant co-morbidity of 30 a variety of pathologies, ranging from cancer and inflammation to metabolic diseases 31 such as diabetes 1 . In the nervous system, where the vasculature is uniquely 32 impermeable and is referred to as the blood-brain barrier (BBB), vascular leakage 33 accompanies stroke, multiple sclerosis, as well as various forms of dementia 2 . 34
Leakage at the blood-retinal barrier (BRB) is a hallmark feature of diabetic retinopathy 35 and neovascular age-related macular degeneration 3 . Leakage during diabetic 36 retinopathy, especially diabetic macular oedema is driven by a multitude of 37 extracellular factors including the angiogenic growth factor vascular endothelial growth 38 factor A (VEGF-A) and VEGF-A antagonists are successfully used to reduce oedema 39 and abnormal vessel growth 4 . Despite remarkable efficacy in restoring vision loss in 40 retinal diseases, intraocular anti-VEGF injections only lead to complete resolution of 41 oedema in about half of the patients 5 , pointing to the existence of VEGF-independent 42 pathogenic leakage pathways as well as potential resistance to anti-VEGFs. In this 43 regard, current R&D focuses on exploring the therapeutic potential of targeting other 44 permeability-inducing factors relevant to retinal leakage diseases such as 45 angiopoeitin-2 6 , lysophosphatidylcholine 7 and bradykinin (BK) 8 . 46
Whilst vascular leakage can be triggered by a wide variety of extracellular molecules, 47 acting on distinct endothelial cell surface receptors, downstream effector mechanisms 48 may be the same to all and ultimately involve paracellular junction modulation or 49 formation of transport vesicles 1,2 . Clearly, endothelial cells regulate hyperpermeability 50 through a core molecular machinery and common, downstream signalling. For 51 instance, calcium (Ca 2+ ) transients, phosphorylation of the MAP kinase p38 and 52 enhanced actin contractility are associated with all leakage events, as is activation of 53 endothelial nitric oxide synthase (eNOS) 9,10,11,12 . Furthermore, VE-cadherin 54
phosphorylation on tyrosines appears to be a prerequisite for paracellular junction 55 modulation 13 . Identifying such core processes, in particular those with components 56 that are highly specific to vascular beds/leakage, could be desirable for therapeutic 57 development as it would render treatment options independent of specific known (or 58 unknown) extracellular leakage inducers. 59
In the brain and the retina, entirely different signalling is induced by VEGF-A in 60 endothelial cells when it is added luminally (from the blood side) or abluminally (from 61 the tissue side), with leakage-inducing signalling entirely restricted to abluminal 62 stimulation 10 . For instance, leakage-associated p38 is triggered by abluminal (basal) 63 VEGF-A stimulation, whilst AKT activation, which does not mediate permeability, is 64 only seen following luminal (apical) stimulation. Thus, signalling specific to leakage 65 can be inferred by comparing cellular stimulation following luminal and abluminal 66 addition of VEGF-A. Conversely, BK efficiently induces permeability from the basal as 67 well as apical side of cerebral or retinal endothelial cells. 68
To identify and validate core components of the leakage machinery in retinal 69 endothelial cells, we adopted an ex vivo retinal preparation, originally described for 70 rats 14 . Development of this method allowed measurement of real time changes of 71 permeability and signalling in intact blood-retinal barrier vessels from rat and mouse. 72 Importantly, this model system was compatible with precise pharmacokinetic agonist 73 studies, parallel IHC staining and manipulation using siRNA. Our workflow can be 74 used to identify core regulators of CNS endothelial hyperpermeability and was 75 validated by identifying the AMP-dependent protein kinase (AMPK) as a novel, key regulator linking VEGF-A or BK-induced Ca 2+ transients to eNOS activation and VE-77 cadherin phosphorylation. 78 79 80 RESULTS 81
Validation of the ex-vivo retinal model 82
In order to study VEGF-A-induced permeability in intact retinal microvessels in real 83 time, we adopted an ex-vivo retinal model 14 . Here the method was validated and 84 developed into a discovery and validation platform of core retinal vascular leakage 85
processes. 86
Immediately after death the head vasculature of rats was perfused and stabilised, and 87 the retinae isolated. Once flatmounted a radial artery was cannulated and the entire 88 retinal vasculature injected with sulforhodamine-B as fluorescent tracer for 89 permeability measurements ( Supplementary Figure 1 ). Subsequently, permeability 90 measurements were carried out by monitoring dye retention continuously by time 91 lapse imaging. A baseline was recorded for at least 30 s, before vasoactive stimulators 92 were added. Permeability (P) values were computed by chosing an area of interest 93 within the dye filled microvessel (Supplemental Figure 2a To assess if the ex vivo preparation and perfusion led to alterations of the retinal 100 vasculature and to determine stability of the preparation, we compared directly 101 perfused fixed retinae with those perfused with cardioplegic solution and then left 102 under superfusion with Krebs solution for 1 h before fixation. Subsequent whole mount 103 staining for the tight junction protein Claudin-5 (CLDN5) and the adherens junction 104 protein VE-cadherin revealed characteristic strands of continuous paracellular staining 105 ( Figure 1a and b) in both preparations. Importantly, the staining pattern was 106 indistinguishable between the two different preparations, indicating that the perfusion 107 did not cause significant disturbances of endothelial junctions. Baseline permeability 108 to sulforhodamine-B was low and on average 0.2 ± 0.16x 10 -6 cm/s. Taken together 109 these data showed that morphological and barrier properties of the retinal 110 microvasculature were well preserved in these preparations. but not BK was abolished following preincubation with SU-1498. 120
This experimental model was also adapted for mouse retinae (Supplemental Figure  121 1g). Baseline permeability in mouse preparations was 0.15 ± 0.1x10 -6 cm/s. VEGF-A 122 stimulation increased permeability to 0.65 ± 0.2x10 -6 cm/s, and this was again 123 sensitive to SU-1498 ( Figure 1i ). Furthermore, we observed SU-1498-sensitive 124 phosphorylation of p38, HSP27 and eNOS in mouse retinal microvessels within 2 min 125 of VEGF-A stimulation (Figure 1j ). To make the model compatible with knockdown 126 technology, mouse eyes were injected intravitreously with siRNA against CLDN5. 127
Western blot analysis of retinal lysates, harvested 72 h after the injection, showed that 128 CLDN5 expression was significantly reduced by 65% (Supplemental Figure 2c 
VEGF-A and Bradykinin induce AMPK phosphorylation 136
In order to find new regulators of leakage, primary rat brain ECs were stimulated for 5 137 or 30 min with VEGF-A (50 ng/ml) from either the apical (non-permeability inducing) 138 or basal (permeability-inducing) side ( Figure 2a ) and cell lysates analysed by a 139 phospho-protein antibody array. In response to VEGF-A stimulation many signalling 140 components were phosphorylated, as exemplified by p38, HSP27, AMPK, eNOS, 141 SRC, ERK and AKT (Figure 2b and 2c) . 142
Differentially phosphorylated proteins were categorised into three groups; group I 143 phosphorylated only after basal stimulation with VEGF-A (such as p38, HSP27 and 144 AMPK), group II phosphorylated regardless of the side of the stimulation (such as 145 eNOS, SRC and ERK) and group III phosphorylated only when VEGF-A was applied 146 apically (such as AKT). Phosphorylation of proteins exclusively in response to basally 147 applied VEGF-A suggested they played a role in hyperpermeability (group I). Among 148 these, AMPK stood out as it has not been linked to endothelial hyperpermeability 149 before. Additionally, its phosphorylation was also very high in response to basally 150 applied VEGF-A when lysates were analysed by phospho-peptide mass spectrometry Next AMPKα was knocked down specifically by intravitreous injection of siRNA 72 h 174 prior to preparing the retinae for ex vivo permeability measurements. Western blot 175 results showed that AMPKα protein expression was significantly reduced by 70% 
VEGF-A-and BK-induced permeability requires Ca 2+ and CaMKK, p38 and eNOS 187
Next, we aimed at placing AMPK within established permeability signalling cascades. 
VEGF-A and BK stimulate VE-Cadherin phosphorylation 217
Phosphorylation of VE-cadherin is central to paracellular microvascular permeability 13 . 218
VEGF-A or BK stimulation of ex vivo retinae induced tyrosine phosphorylation of VE-219
cadherin on Y658 in intact microvessels (Figure 6b ). This phosphorylation was 220 completely abolished following pre-incubation with compound C, L-NAME but not 221 SB203580, indicating that VE-cadherin was downstream of AMPK/eNOS but not 222 AMPK/p38 ( Figure 6c ). Measuring retinal microvascular permeability has been mainly restricted to Miles-type 228 assays using either fluorescent tracers or Evans Blue/albumin 7,19 . Chronic leakage 229
can also be visualised in real time by fluorescein angiography 20 . However, collectively 230 these methods, which measure the amount of extravasated tracer, do not only reflect 231 the degree of leakage but are also strongly influenced by dye concentration in the 232 vasculature and dye clearance from the tissue 1,2 . Further disadvantages of these 233 methods are that compound concentrations and timing cannot be controlled 234 accurately. Thus, they are completely inadequate to measure acute permeability and 235 associated signalling. 236
The ex-vivo retinal platform described herein addressed most of these issues. It 237 constituted a significant advance to endothelial cell cultures, since it used a complete 238 and intact neurovascular unit. The functionality of the retinal vasculature was 239 preserved, with both VE-cadherin and CLDN5 distribution indistinguishable from that 240 in vivo. Similar preparations of the brain and the retina also display full cellular 241 functionality of e.g. pericytes 21 . Importantly, permeability to sulforhodamine-B was 242 very low and within the range of that of the intact BBB in vivo 22 and notably ca. 10 x 243 lower than in preparations of pial micorvessels 23 . 244
Vascular barrier properties in these retinal explants was, as expected dependent on 245 tight junction integrity. The reported speed, at which compounds such as VEGF-A 246 induce permeability 24 , was fully recapitulated. Leakage measurements were then 247 combined with whole tissue staining and analyses of the phosphorylation status of key 248 mediators of permeability using phospho-specific antibodies to gain mechanistic 249
insight. Furthermore, the preparations could be interrogated using small molecule 250
antagonists and agonists at defined concentrations and times allowing for the 251 identification of key downstream regulators, common to VEGF-A and BK stimulation. 252
Even more specific neutralisation of key proteins was achieved through prior 253 intraocular injection of siRNA. Conceivably this model is compatible for use with 254 genetically modified mice and disease models, further broadening its applicability. The 255 ex vivo platform could also be used to measure Ca 2+ transients or localised production 256 of reactive oxygen or nitrogen species in response to vasoactive compounds such as 257
VEGF or BK. 258
Measurements in retinae were done ex vivo, in the absence of blood flow. Blood flow 259 and associated shear stress may influence endothelial cell biology, such as cell-cell 260 adhesion and inflammatory dysfunction 13,25,26 and their absence in our preparation 261 must be taken into account when evaluating results. However, it should also be noted 262 that permeability regulation by shear stress appears to be remembered in ECs in vitro 263 for at least 24 h 27 . 264
For the purpose of developing and validating the ex vivo retinal platform we have 265 focused on permeability factors, which induce permeability when added to the 266 abluminal (tissue) side of the endothelium, such as VEGF-A and BK 10 , as these are 267 readily applied on top of the retinal explants. Other permeability factors that act only 268 from the luminal side, such as lysophosphatidic acid 10 or lysophosphatidylcholine 7 , 269 could also potentially be investigated in this system. However, this would require the 270 use of a manifold injection system 28 , which allows switching between injection of 271 sulforhodamine-B with or without permeability factor into radial vessels. 272
VEGF-A and BK induced acute leakage in retinal microvessels, which was associated 273
with and dependent on Ca 2+ , the MAPK p38 and eNOS, in agreement with published 274 data 9,10,12 . We also identified AMPK as a novel, key regulator of both VEGF-A-and 275 BK-induced permeability, indicating it is a core regulator of vascular permeability. This 276 protein kinase is primarily known to regulate energy requirements of the cell, but has 277 also been implicated in other seemingly unrelated cellular processes such as 278 migration, cell growth and apoptosis 29 , but crucially not yet in endothelial permeability. 279
Whilst its canonical activation is dependent on cellular AMP: ATP concentrations and 280 phosphorylation on T172 by LKB1, we found that, in the regulation of endothelial 281 permeability, AMPK was activated downstream of Ca 2+ and CaMKKβ. This activation 282 pathway has previously been described as non-canonical 30 and is also operational 283 when CNS endothelial cells facilitate the transmigration of lypmphocytes 15 . Notably, 284
VEGF-A has been reported before to induce NO production via a pathway requiring 285 Ca 2+ and AMPK 31 . Indeed, eNOS phosphorylation on S1179 can be mediated by 286
AKT 32 or AMPK 15,33 . However, AKT activity is not relevant to permeability induction in 287 neurovascular endothelial cells, as it is not activated in response to permeability-288 inducing (abluminal) VEGF-A stimulation 10 . We confirmed the phosphorylation of 289 eNOS on S1179 downstream of AMPK both in response to VEGF-A and BK 290 stimulation and its requirement for successful permeability induction. Interestingly, the 291 Ca 2+ /AMPK/eNOS pathway resulted in the phosphorylation of VE-cadherin on Y658, 292 identified previously as important for vascular permeability 13 , thus providing a direct 293 link between AMPK and paracellular junction regulation. AMPK regulation of this cascade was operational during VEGF-A or BK-induced 300 permeability, we favour an alternative model of direct activation of p38 by AMPK via 301 TAB1, a pathway described in apoptotic lymphocytes and the ischemic heart 36, 37 . By 302 switching between two different p38 activation modes (Ca 2+ /AMPK/TAB1 versus 303 cdc42/PAK) endothelial cells could adapt cytoskeletal regulation to the specific 304 requirement of endothelial cell migration or permeability. 305
The reliable permeability and signalling measurement of ex vivo retina platform 306 provides all the necessary requirements to identify novel key mediators of vascular 307 leakage and test their druggability. Whilst AMPK clearly emerged as such a key 308 regulator, it is unlikely to be exploitable as a target for anti-leakage treatments: its 309 central role in regulating cellular energy demands throughout the body hints at many 310 potential side effects. Activation of AMPK is currently investigated as a therapeutic 311 option to treat cancer, metabolic syndrome and diabetes 38, 39 . However, in light of the 312 strong induction of permeability we observed in response to at least two AMPK 313 agonists, we propose that these avenues should be explored cautiously, since 314 microvascular leakage may accompany such treatment modalities. Nevertheless, this 315 discovery indicated that the ex vivo retina platform can play an important part in future 316 discoveries of anti-leakage drug targets. 
Retinal explant preparation 360
Wistar female rats were killed by overdose of CO2. Rats were placed in a lateral 361 decubitus position under the dissection microscope and were securely maintained with 362 tape. The skin of the neck region was gently cut off and an incision of approximately 363 15 mm over the thyroid bone exposed the salivary glands which were gently pushed 364 sideways, uncovering the neighbouring muscles. Lateral traction of the 365 aforementioned muscles enabled visual access to the common carotid artery. Then 366 the common carotid artery was carefully exposed, elevated and separated from the 367 vagus nerve using forceps and a 7-0 suture which was initially placed below the artery 368 and later used to tie securely a microcannula after its insertion. A small cut was 369 
Western Blots 448
Cell lysates were prepared as previously described 10 . Proteins were separated by 449 SDS-PAGE and transferred to nitrocellulose by semidry electrotransfer. Membranes were blocked o/n and then incubated with the appropriate antibody diluted at 1:2,000. 451
Membranes were washed three times with TBS/0.1% Tween-20 before 1h incubation 452 with an anti-mouse or anti-rabbit HRP-conjugated IgG (GE Healthcare) at a dilution of 453 1:10,000 and 1:5,000, respectively. Membranes were developed using the ECL 454 reagents (Roche) and exposed to X-ray film. Protein bands were evaluated by 455 densitometric quantification, normalized against the amount of total protein, and 456 GADPH or Tubulin. were then applied to the top of the retina and changes in fluorescence were recorded (c, d) or phosphorylation of p38, HSP27 and eNOS was assessed by staining (e, f). (g-l) AMPKα was knocked down by intravitreous injection of a specific siRNA (g, h) and ex-vivo retinae were isolated after at least 48h. VEGF-A (50 ng/ml) (I, k) or BK (10 μM) (j, l) did not induce any permeability in the knocked down exvivo retina. Representative results and quantifications (normalized mean ± SEM) from three independent experiments are shown. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars, 10 μm. 
Figure 6. VEGF-A and Bradykinin induced VE-Cadherin phosphorylation (a)
Ex-vivo retinae were preincubated with SU1498 (10 µM), or BAPTA (20 µM) or STO (10 µM) and treated with VEGF-A and Brdykinin for 2 min. Retinae were then fixed with 4% PFA and whole mount stained for phospho-AMPKα (magenta) against IB4 (green). (b) Ex-vivo retinae were preincubated with compound C (10 µM), or L-NAME (10 µM) or SB202190 (10 µM), treated with VEGF-A and Bradykinin for 2 min and whole mount stained for phospho-VE-Cadherin (magenta) against IB4 (green). 
